|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||110.93 - 115.96|
|52 Week Range||96.18 - 149.34|
|PE Ratio (TTM)||50.00|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Twenty-one analysts are tracking Alexion Pharmaceuticals in December 2017. Six of them are recommending a “strong buy,” while 12 are recommending a “buy.”
Biotech mergers and acquisitions, which were quite lean in 2017, may pick up significantly in 2018 if the proposed tax reforms are finally approved.
In 3Q17, Alexion Pharmaceuticals' (ALXN) Strensiq generated revenues of $87 million compared to $61 million in 3Q16, a 43% growth YoY and a 5% growth QoQ.
If Alexion failed to offer more aggressive financial performance guidance or consider strategic alternatives such as a sale, Elliott could start a proxy fight to claim board seats, the paper reported, citing people who were not authorized to speak publicly. In a recent meeting between Alexion and Elliott, the hedge fund sought to have more biotech experts as directors and suggested four potential candidates, the newspaper said. "Alexion believes in active and constructive dialogue with all of our shareholders, and we value their perspective," a company spokeswoman said in an emailed statement on Friday.
U.S. hedge fund Elliott Management, which has built a stake in Alexion Pharmaceuticals, is urging the company to take more action to boost its stock price, including exploring a sale, the New York Times reported on Thursday. If Alexion failed to offer more aggressive financial performance guidance or consider strategic alternatives such as a sale, Elliott could start a proxy fight to claim board seats, the paper reported, citing people who were not authorized to speak publicly. In a recent meeting between Alexion and Elliott, the hedge fund sought to have more biotech experts as directors and suggested four potential candidates, the newspaper said.
In 3Q17, Alexion Pharmaceuticals’ (ALXN) Soliris generated revenues of $756 million, a 4% growth YoY (year-over-year) and a 7% fall QoQ (quarter-over-quarter).
Shares of Alexion Pharmaceuticals (ALXN) shot to the top of the S&P 500 today, on reports that an activist investor is pushing for more shareholder value creation. Alexion rose $7.68, or 7.2% to $114.46, while the S&P 500 climbed 14.52 points, or 0.6%, to 2651.50. The stock jumped after reports that the hedge fund Elliott Management, is urging the company to make more changes.
Alexion could see as much as 30% upside if its rare blood disease drug outperforms its approved drug Soliris in a pair of Phase 3 trials.
In 3Q17, Alexion Pharmaceuticals (ALXN) generated revenues of $859 million, which represented an 8% growth YoY (year-over-year) and a 6% fall QoQ (quarter-over-quarter).
One sector group in particular looks ready to profit from the upward drift are the biotech stocks, which have been on the decline in recent weeks as investors focus on Big Tech stocks and more recently on high-tax issues most likely to benefit from the GOP’s corporate tax cut plans.
Shares of Alexion Pharmaceuticals (ALXN) are jumping on Friday, following reports that activist investor Elliott Management is pushing for changes at the company. Alexion has had a tough year, falling some 7% since the start of 2017, a year that has seen the iShares Nasdaq Biotechnology ETF (IBB) and SPDR S&P Biotech ETF (XBI) climb double digits, so it's no surprise that investors are annoyed. Elliott Management, which has built a stake in the company, is urging Alexion to do more to boost its shares, according to sources close to the situation that could only speak to the New York Times anonymously. Of course Elliott Management is no stranger to picking fights with companies, as its previously sparred with Samsung Electronics ( 009530KS ) and waged a proxy battle at Arconic (ARNC).
Activist hedge fund Elliott Management has targeted two high-profile local companies in recent years, pushing for changes at EMC before it was acquired by Dell, and, more recently, instigating cost-cutting measures at Watertown-based health IT firm athenahealth. According to a New York Times report late Thursday, Elliott has now set its sights on Alexion Pharmaceuticals (ALXN), a rare disease drugmaker that is planning to move its headquarters from Connecticut to Boston next year. The newspaper, citing two unnamed sources with knowledge of Elliott’s plans, said that the hedge fund has taken a stake in Alexion and is urging the company “to do more to lift its stock price.” The report raised the possibility that Elliott could launch a proxy battle to gain seats on Alexion’s board, or even push for a sale, if the company doesn’t meet its demands.
A report says activist hedge fund Elliott Management wants plans to boost Alexion's share price or it will start a proxy fight for seats on the board.
Alexion Pharmaceuticals shares saw a handy gain early on Friday after the New York Times reported that there might be some increasing activist movement in the stock.
Among the companies with shares expected to trade actively in Friday's session are Amazon.com, Caterpillar, Alexion Pharmaceuticals, 3M, United Continental and American Outdoor.
The following are the top stories on the New York Times business pages. Reuters has not verified these stories and does not vouch for their accuracy. - Ford Motor Co is shifting production of a future ...
After a four day losing streak U.S. stocks closed higher on Thursday with the S&P 500 and the Dow Jones Industrial Average both gaining 0.3%, while the the Nasdaq Composite gained 0.5%. Asia-Pacific markets ...
The Cambridge, Mass.-based firm unveiled positive top-line results from its Phase 2 study of SAGE-217 in patients with moderate to severe major depressive disorder.